Accelerating Biologic Discovery with Confidence

Mosaic Biosciences is a consultative discovery partner for innovators advancing antibody and protein therapeutics. Our end-to-end model integrates in vivo antibody discovery, in vitro display technologies, antibody discovery, protein engineering, bespoke assay development, and early developability analytics to support confident decision-making from target validation through candidate selection.

Learn More About Our Technology

Mosaic provides:

End-to-end antibody & protein discovery workflows
In vitro & in vivo functional screening and characterization
Protein engineering & optimization
Hit identification, lead selection, and candidate refinement
Rapid iteration guided by data-driven insights

Scientist using mechanical pipettor to perform protein engineering services.

Learn more about Mosaic

Our approach for success

Transforming concepts into  clinical candidates

By combining exclusive access to next-generation technology with integrated scientific workflows under one roof, Mosaic simplifies discovery, reduces handoffs, and delivers predictable outcomes.

Protein Design & Engineering

Computational and experimental protein engineering including library-based optimization, humanization, multispecific and bispecific design, expression optimization, and iterative refinement cycles informed by biophysical and functional data.

Discover Protein Design & Engineering solution
Antibody Discovery & Optimization

Integrated in vivo and in vitro discovery workflows using wild-type, hyperimmune, camelid, and humanized/transgenic mouse platforms, combined with proprietary phage and yeast display platforms for de novo discovery and optimization. Early functional screening and developability analytics ensure rank-ordered leads are ready for downstream development.

Discover Antibody Discovery & Optimization solution

Explore all solutions

Why Mosaic for Antibody Discovery and Protein Engineering?

Biologic discovery is inherently complex, and fragmented workflows increase risk. Mosaic integrates the full discovery continuum into a single, accountable partnership.

Exclusive FHD Technology Access

Next-generation, fully human transgenic mouse platform delivering broad sequence and epitope diversity.

Integrated End-to-End Workflow

Discovery, engineering, analytics, and pharmacology under one roof.

Function-First Screening

Bespoke cell-based assays tied to biological mechanism, not convenience

Early Developability Assessment

Stability, aggregation, and biophysical profiling early in discovery

Freedom to Operate

Milestone-based, royalty-free access options for downstream clarity

Learn Who We Partner With

Meet Our Experts

Eric Furfine PhD

Chief Scientific Officer

Eric brings experience in leadership roles in biotechnology and pharmaceutical companies to the role of Chief Scientific Officer at Mosaic.

He is a visionary leader and drug hunter in the biotech and pharmaceutical industry. As CSO and President of R&D at Eleven Biotherapeutics, his leadership drove an IPO that financed Phase 3 clinical studies and a lucrative licensing deal on a second therapeutic asset. His building the Adnectin protein therapeutic discovery platform at Adnexus resulted in the acquisition of the company by BMS, where subsequently five adnectins were advanced into clinical studies. As VP Preclinical Development at Regeneron, he played pivotal roles in developing game-changing drugs, such as Eylea.

Eric received his PhD in Biochemistry from Brandeis University
Scott Glaser PhD

SVP, Biologics Discovery

Scott brings 30+ years of experience in biologic drug discovery to Mosaic’s partners.

Scott previously served as Director of Antibody Therapeutics for Novartis (GNF) where he led antibody discovery and platform development efforts. Scott also worked at Pfizer as Sr. Director/ Site Head of the San Diego Centers for Therapeutic Innovations where he built the discovery team and participated in implementing CTI’s model for academic-industry collaboration. Prior to Pfizer, Scott led Antibody Therapeutics at Biogen Idec.

Over his career Scott has contributed to over 50 discovery programs, with multiple molecules advancing into clinical development. He has also pioneered protein technologies, demonstrated by his co-inventorship of 23 issued US patents and multiple pending applications.
Alexei Kazantsev PhD

Sr. Director Protein Design and Engineering

Alexei leads the Protein Design and Engineering team as well as multiple parter programs

He is a gifted scientist with domain expertise spanning structural and chemical biology, protein engineering, and tissue engineering. At Mosaic Biosciences, he spearheaded efforts to optimize the pharmacokinetic properties and selectivity of therapeutic protein candidates and led the design and development of hydrogel matrices for drug delivery and tissue regeneration. Prior to joining Mosaic, he conducted structural biology research on RNA and proteins using X-ray crystallography and SAXS techniques. Alexei received his PhD in Biochemistry from Indiana University Bloomington.

Attempts to keep up with sons in climbing gym
Tracey Mullen

Chief Strategy Officer

Tracey Mullen brings extensive experience in both drug discovery and biopharma commercial development. Prior to joining Mosaic, Tracey served as Senior Vice President of Biopharma at Twist Biosciences, which she joined through the acquisition of Abveris in November of 2021. At Twist, Tracey managed the Biopharma Solutions business unit, which included the integrated legacy Twist Biopharma and Abveris teams. Prior to Twist, she served as CEO of Abveris, a company offering premium in vivo antibody drug discovery services. Tracey initially served as Abveris’ Chief Operating Officer where she managed operations and project development for both therapeutic and critical reagent in vivo antibody discovery campaigns. Before Abveris, she served on the antibody discovery team at Biogen where she helped implement the technology transfer of the Adimab yeast display platform for antibody discovery and engineering. Previously she worked for Abpro, a contract research organization specializing in in vivo antibody discovery.

Tracey received her B.S. in Chemical and Biological Engineering from the Massachusetts Institute of Technology and her Executive MBA from Quantic School of Business and Technology